Across TCGA pan-cancer cohorts, CARD9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CARD9 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher CARD9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CARD9 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

GBM, HNSC, and LSCC are the cancer types where CARD9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.268	0.455	.007	9	view →
HNSC	DFS	Quartile	III,IV	1.000	0.500	.036	2	view →
LSCC	DFS	Median	II,III,IV	0.871	0.963	.049	1	view →
CCRCC	DFS	Median	All	0.847	0.650	.043	1	view →
LUAD	DFS	Tertile	All	0.720	0.472	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: CARD9 tumor-vs-normal RNA expression · all CARD9 data types